ConductScience.org, home
A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)
API referenceFor AI assistants

Trial · NCT03692871

Results by group138

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 138

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percentage of Participants With a Solicited Injection-site Adverse EventV114Injection-site erythema43.9Percentage of participants
Percentage of Participants With a Solicited Injection-site Adverse EventPrevnar 13™Injection-site erythema36.0Percentage of participants
Percentage of Participants With a Solicited Injection-site Adverse EventV114Injection-site induration25.3Percentage of participants
Percentage of Participants With a Solicited Injection-site Adverse EventPrevnar 13™Injection-site induration25.6Percentage of participants
Percentage of Participants With a Solicited Injection-site Adverse EventV114Injection-site pain42.9Percentage of participants
Percentage of Participants With a Solicited Injection-site Adverse EventPrevnar 13™Injection-site pain36.5Percentage of participants
Percentage of Participants With a Solicited Injection-site Adverse EventV114Injection-site swelling27.9Percentage of participants
Percentage of Participants With a Solicited Injection-site Adverse EventPrevnar 13™Injection-site swelling23.3Percentage of participants
Percentage of Participants With a Solicited Systemic Adverse EventV114Decreased appetite41.6Percentage of participants
Percentage of Participants With a Solicited Systemic Adverse EventPrevnar 13™Decreased appetite36.0Percentage of participants
Percentage of Participants With a Solicited Systemic Adverse EventV114Irritability74.9Percentage of participants
Percentage of Participants With a Solicited Systemic Adverse EventPrevnar 13™Irritability69.3Percentage of participants
Percentage of Participants With a Solicited Systemic Adverse EventV114Somnolence55.4Percentage of participants
Percentage of Participants With a Solicited Systemic Adverse EventPrevnar 13™Somnolence55.0Percentage of participants
Percentage of Participants With a Solicited Systemic Adverse EventV114Urticaria5.9Percentage of participants
Percentage of Participants With a Solicited Systemic Adverse EventPrevnar 13™Urticaria6.7Percentage of participants
Percentage of Participants With a Vaccine-related Serious Adverse EventV1140.1Percentage of participants
Percentage of Participants With a Vaccine-related Serious Adverse EventPrevnar 13™0Percentage of participants
Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) at 30 Days After Vaccination 3 (Premature Infants Only)V114Serotype 11.1595% Confidence Interval 0.88 to 1.52μg/mL
Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) at 30 Days After Vaccination 3 (Premature Infants Only)Prevnar 13™Serotype 11.6195% Confidence Interval 1.25 to 2.09μg/mL

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03692871/results

API referenceFor AI assistants